Pursuit Wealth Management LLC Acquires Shares of 5,826 Gilead Sciences, Inc. $GILD

Pursuit Wealth Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 5,826 shares of the biopharmaceutical company’s stock, valued at approximately $715,000.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC lifted its position in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares in the last quarter. Ieq Capital LLC lifted its position in Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after buying an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC boosted its stake in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $139.77 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock’s 50 day moving average is $144.86 and its 200-day moving average is $131.05. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a market capitalization of $173.49 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 1.87 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: PEPFAR/The Global Fund and the U.S. State Department expanded funding for Gilead’s twice‑yearly injectable HIV prevention drug lenacapavir, committing to supply up to an additional 1 million people (bringing total commitment to ~3 million through 2028). This materially increases potential volume and global uptake for a key growth product and supports longer‑term revenue visibility. PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir
• Positive Sentiment: At least one brokerage note flagged upside for GILD (Citigroup analyst expectation for a higher stock price), which can help underpin investor sentiment ahead of earnings. Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Gilead is expected to report quarterly results this week — a clear near‑term catalyst that could drive volatility as revenues, guidance and commentary on product uptake (notably lenacapavir) are digested. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Recent market commentary noted a modest intraday gain for GILD but that it lagged broader market moves — signaling mixed investor reaction to current headlines. Here’s Why Gilead Sciences (GILD) Gained But Lagged the Market Today
• Negative Sentiment: Zacks Research trimmed EPS estimates across multiple quarters and cut FY2026 EPS (Q1: 1.81→1.76; Q2: 2.05→2.00; Q3: 2.30→2.25; Q4: 2.39→2.34; FY: 8.54→8.34). Those downward revisions reduce near‑term earnings expectations and can put pressure on the stock ahead of reported results, especially if Gilead’s guidance or drug‑sales trends come in weaker than the lowered bar.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft raised their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. UBS Group boosted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Rothschild & Co Redburn boosted their target price on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Barclays assumed coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $156.77.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This trade represents a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 293,280 shares of company stock valued at $42,074,690. 0.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.